Package Leaflet: Information for the User

Irbesartán Stada 150 mg Tablets EFG

Read this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others even if they have the same symptoms as you, as it may harm them.
• If you experience any side effects, talk to your doctor or pharmacist. See section 4.

Table of Contents

1.What is Irbesartán Stada and what it is used for

2.What you need to know before taking Irbesartán Stada

3.How to take Irbesartán Stada

4.Possible side effects

5.Storage of Irbesartán Stada

6.Contents of the pack and additional information

Irbesartán belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that binds to receptors, causing blood vessels to constrict. This results in an increase in blood pressure. Irbesartán prevents angiotensin-II from binding to these receptors, relaxing blood vessels and reducing blood pressure. Irbesartán slows the deterioration of renal function in patients with high blood pressure and type 2 diabetes.

Irbesartán is used in adult patients

• to treat high blood pressure (essential hypertension)

to protect the kidneys in patients with high blood pressure, type 2 diabetes, and clinical evidence of altered renal function.

Do not take Irbesartán Stada

• if you areallergicto irbesartán or any of the other components of this medication (listed in section 6)
• if you aremore than 3 months pregnant.(In any case, it is better to avoid taking this medication also at the beginning of your pregnancy – see Pregnancy section)
• if you havediabetes or kidney insufficiencyand are being treated with a medication to lower blood pressure that contains aliskirén

Warnings and precautions

Consult your doctor before starting to take Irbesartán Stada andif any of the followingaspects affect you:

• if you haveexcessive vomiting or diarrhea
• if you havekidney problems
• if you haveheart problems
• if you are taking irbesartán fordiabetic nephropathy. In this case, your doctor may perform regular blood tests, especially to measure potassium levels in case of renal function deterioration
• if you presentlow blood sugar levels(symptoms may include sweating, weakness, hunger, dizziness, tremors, headache, flushing or paleness, numbness, rapid and strong heartbeats), especially if you are being treated for diabetes
• ifyou are to be operated(surgical intervention) orif you are to be administered anesthetics
• if you are taking any of the following medications used to treat high blood pressure (hypertension):

-a converting enzyme inhibitor (ACEI) (for example enalapril, lisinopril, ramipril), particularly if you have kidney problems related to diabetes.

-aliskirén.

Consult your doctor if you present abdominal pain, nausea, vomiting or diarrhea after taking Irbesartán Stada. Your doctor will decide whether to continue with the treatment. Do not stop taking Irbesartán Stada on your own.

Your doctor may monitor your renal function, blood pressure, and electrolyte levels in the blood (such as potassium), at regular intervals.

See also the information under the heading “Do not take Irbesartán Stada”.

If you are pregnant, if you suspect you may beor if you plan to becomepregnant, inform your doctor. Irbesartán is not recommended for use at the beginning of pregnancy (first 3 months), and in no case should it be administered from the third month of pregnancy, as it may cause serious harm to your baby (see Pregnancy section).

Children and adolescents

This medication should not be used in children and adolescents as its safety and efficacy have not been fully established.

Other medications and Irbesartán Stada

Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.

Your doctor may need to modify your dose and/or take other precautions:

if you are taking a converting enzyme inhibitor (ACEI) or aliskirén (see also the information under the headings “Do not take Irbesartán Stada” and “Warnings and precautions”).

You may need to have blood tests if you are taking:

• potassium supplements
• potassium-sparing salt substitutes
• potassium-saving medications (such as certain diuretics)
• medications containing lithium
• repaglinide (a medication used to reduce blood sugar levels).

If you are using a type of analgesic, known as nonsteroidal anti-inflammatory drugs (NSAIDs), the effect of irbesartán may be reduced.

Irbesartán Stada intake with food and beverages

Irbesartán can be taken with or without food.

Pregnancy and lactation

If you are pregnant, breastfeeding, or suspect you may beor plan to becomepregnant, consult your doctor or pharmacist before using this medication.

Pregnancy

You should inform your doctor if you are pregnant, if you suspect you may beor if you plan to becomepregnant. Your doctor will usually advise you to stop taking irbesartán before becoming pregnant or as soon as you become pregnant and recommend taking another antihypertensive medication instead. Irbesartán is not recommended for use at the beginning of pregnancy and should not be administered from the third month of pregnancy as it may cause serious harm to your baby when administered from that point onwards.

Lactation

Inform your doctor if you plan to start or are breastfeeding, as irbesartán is not recommended for use during this period. Your doctor may decide to administer a more suitable treatment if you want to breastfeed, especially for newborns or premature babies.

Driving and operating machines

It is unlikely that irbesartán will affect your ability to drive vehicles or operate machines. However, during hypertension treatment, occasional dizziness or fatigue may occur. If you experience these symptoms, inform your doctor before driving or operating machines.

Irbesartán Stada contains lactose and sodium

This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.

This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially “sodium-free”.

Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.

Administration Method

Irbesartán Stada is administeredorally. The tablets should be swallowed with a sufficient amount of liquid (e.g., a glass of water). Irbesartán can be taken with or without food. You should try to take your daily dose at the same time every day. It is essential to continue taking this medication until your doctor advises you otherwise.

• Patients with High Blood Pressure

The usual dose is 150 mg once a day. Subsequently, and depending on the blood pressure response, this dose may be increased to 300 mg once a day (two tablets a day).

• Patients with High Blood Pressure and Type 2 Diabetes with Kidney Damage

In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of associated kidney damage is 300 mg once a day (two tablets a day).

Your doctor may advise a lower dose, especially at the beginning of treatment, in certain patients, such as those undergoinghemodialysisor thoseover 75 years old.

The maximum blood pressure-lowering effect should be achieved within 4-6 weeks after starting treatment.

Use in Children and Adolescents

Irbesartán should not be administered to children under 18 years old. If a child swallows several tablets, contact your doctor immediately.

If You Take More Irbesartán Stada Than You Should

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.

If You Forget to Take Irbesartán Stada

If you accidentally forget to take a dose, simply take your regular dose when it is due next. Do not take a double dose to compensate for the missed doses.

If you have any other questions about the use of this medication, consult your doctor or pharmacist.

Like all medicines, this medicine may cause side effects, although not everyone will experience them.

However, some of these side effects may be serious and may require medical attention.

Like with similar medicines, in rare cases, cases of skin allergic reactions (skin rash, urticaria) have been reported in patients treated with irbesartán, as well as localized inflammation in the face, lips, and/or tongue. If you think you may have this type of reaction or experience shortness of breath,stop taking irbesartán and seek immediate medical attention.

The side effects mentioned below are grouped by frequency:

Very frequent: may affect more than 1 in 10 people.

Frequent: may affect up to 1 in 10 people.

Infrequent: may affect up to 1 in 100 people.

The side effects reported in clinical trials conducted in patients treated with irbesartán were:

• Very frequent(may affect more than 1 in 10 people): if you have high blood pressure and type 2 diabetes with kidney damage, blood tests may show an increase in potassium levels.

• Frequent(may affect up to 1 in 10 people): dizziness, nausea/vomiting, fatigue, and blood tests may show elevated levels of an enzyme that measures muscle and heart function (creatine kinase). In patients with high blood pressure and type 2 diabetes with kidney damage, dizziness (especially when standing up), low blood pressure (especially when standing up), muscle or joint pain, and decreased levels of a protein present in red blood cells (hemoglobin).

• Infrequent(may affect up to 1 in 100 people): tachycardia, skin redness, cough, diarrhea, indigestion/heartburn, sexual dysfunction (sexual function alterations), and chest pain.

• Rare(may affect up to 1 in 1000 people): intestinal angioedema: intestinal swelling that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea.

Since the marketing of irbesartán, some side effects have been reported. The side effects observed with unknown frequency are: feeling of spinning, headache, taste alteration, ringing in the ears, muscle cramps, muscle and joint pain, decrease in the number of red blood cells (anemia – symptoms may include fatigue, headaches, difficulty breathing during exercise, dizziness, and paleness), reduction in the number of platelets, abnormal liver function, increased potassium levels in the blood, kidney function insufficiency, inflammation of small blood vessels, mainly in the skin area (condition known as leukocytoclastic vasculitis), severe allergic reactions (anaphylactic shock), and low blood sugar levels. Also, cases of rare jaundice (yellowing of the skin and/or white of the eyes) have been observed.

Reporting of side effects:

If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.

Keep out of the sight and reach of children.

Do not use this medicine after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.

Store in the original packaging to protect it from light.

Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.

Composition ofIrbesartánStada

-The active ingredient is irbesartan. Each tablet contains 150 mg of irbesartan.

-The other components are: povidone (E-1201), magnesium stearate, microcrystalline cellulose (E-460), lactose monohydrate, sodium croscarmellose, anhydrous colloidal silica, hydrogenated ricin oil, cornstarch.

Appearance of the product and content of the packaging

The Irbesartán Stada 150 mg tablets are white, round, biconvex, and scored.

The score is only for breaking the tablet if it is difficult to swallow whole.

The Irbesartán Stada 150 mg tablets are presented in blister packaging of 28 tablets

Holder of the marketing authorization andresponsible for manufacturing

Holder of the marketing authorization:

STADA Laboratory, S.L.

Frederic Mompou, 5

08960, Sant Just Desvern (Barcelona)

Spain

[email protected]

Responsible for manufacturing

Liconsa Laboratories, S.A.

Avd. Miralcampo, nº 7

Polígono Industrial Miralcampo

19200 Azuqueca de Henares (Guadalajara)

Spain

Date of the last review of this leaflet:February 2025

The detailed and updated information on this medication is availableonthe website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/